TY - JOUR
T1 - The World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of bipolar disorders
T2 - Update 2010 on the treatment of acute bipolar depression
AU - WFSBP Task Force On Treatment Guidelines For Bipolar Disorders
AU - Grunze, Heinz
AU - Vieta, Eduard
AU - Goodwin, Guy M.
AU - Bowden, Charles
AU - Licht, Rasmus W.
AU - Mller, Hans Jrgen
AU - Kasper, Siegfried
AU - Möller, Hans Jürgen
AU - Akiskal, Hagop
AU - Ayuso-Gutierrez, José Luis
AU - Bauer, Michael
AU - Bech, Per
AU - Berk, Michael
AU - Bitter, Istvan
AU - Burrows, Graham
AU - Calabrese, Joseph
AU - Cassano, Giovanni
AU - Cetkovich-Bakmas, Marcelo
AU - Cookson, John C.
AU - Ferrier, I. Nicol
AU - Gattaz, Wagner F.
AU - Goodwin, Frederik K.
AU - Heinze, Gerhard
AU - Higuchi, Teruhiko
AU - Hirschfeld, Robert M.
AU - Hoeschl, Cyril
AU - Holsboer-Trachsler, Edith
AU - Jamison, Kay Redfield
AU - Katona, Cornelius
AU - Keller, Martin
AU - Kostukova, E.
AU - Kruger, Hever
AU - Kulhara, Parmanand
AU - Lecruibier, Yves
AU - Larach, Veronica
AU - Lingjaerde, Odd
AU - Lublin, Henrik
AU - Maj, Mario
AU - Mendlewicz, Julien
AU - Camacho, Roberto Miranda
AU - Mitchell, Philip
AU - Mosolov, S.
AU - Montgomery, Stuart
AU - Nemeroff, Charles
AU - Nolen, Willem
AU - Paykel, Eugene S.
AU - Post, Robert M.
AU - Puzynski, Stanislaw
AU - Rihmer, Zoltan
AU - Rybakowski, Janusz K.
N1 - Funding Information:
Charles Bowden received grants/research support, consulting fees and honoraria within the last 3 years from Abbott Laboratories, Astra Zeneca, Bristol-Myers Squibb, GlaxoSmithKline, Janssen, JDS Inc., Lilly Research, National Institute of Mental Health, Pfizer, R.W. Johnson Pharmaceutical Institute, Sanofi -Aventis, Repligen and the Stanley Medical Research Foundation.
PY - 2010/1/1
Y1 - 2010/1/1
N2 - Objectives. These guidelines are based on a first edition that was published in 2002, and have been edited and updated with the available scientific evidence until September 2009. Their purpose is to supply a systematic overview of all scientific evidence pertaining to the treatment of acute bipolar depression in adults. Methods. The data used for these guidelines have been extracted from a MEDLINE and EMBASE search, from the clinical trial database clinicaltrials.gov, from recent proceedings of key conferences, and from various national and international treatment guidelines. Their scientific rigor was categorised into six levels of evidence (AF). As these guidelines are intended for clinical use, the scientific evidence was finally assigned different grades of recommendation to ensure practicability. Results. We identified 10 pharmacological monotherapies or combination treatments with at least limited positive evidence for efficacy in bipolar depression, several of them still experimental and backed up only by a single study. Only one medication was considered to be sufficiently studied to merit full positive evidence. Conclusions. Although major advances have been made since the first edition of this guideline in 2002, there are many areas which still need more intense research to optimize treatment. The majority of treatment recommendations is still based on limited data and leaves considerable areas of uncertainty.
AB - Objectives. These guidelines are based on a first edition that was published in 2002, and have been edited and updated with the available scientific evidence until September 2009. Their purpose is to supply a systematic overview of all scientific evidence pertaining to the treatment of acute bipolar depression in adults. Methods. The data used for these guidelines have been extracted from a MEDLINE and EMBASE search, from the clinical trial database clinicaltrials.gov, from recent proceedings of key conferences, and from various national and international treatment guidelines. Their scientific rigor was categorised into six levels of evidence (AF). As these guidelines are intended for clinical use, the scientific evidence was finally assigned different grades of recommendation to ensure practicability. Results. We identified 10 pharmacological monotherapies or combination treatments with at least limited positive evidence for efficacy in bipolar depression, several of them still experimental and backed up only by a single study. Only one medication was considered to be sufficiently studied to merit full positive evidence. Conclusions. Although major advances have been made since the first edition of this guideline in 2002, there are many areas which still need more intense research to optimize treatment. The majority of treatment recommendations is still based on limited data and leaves considerable areas of uncertainty.
KW - Acute treatment
KW - Antidepressants
KW - Antipsychotics
KW - Bipolar disorder
KW - Depression
KW - Electroconvulsive therapy
KW - Evidence-based guidelines
KW - Mood stabiliser
KW - Pharmacotherapy
KW - Psychotherapy
UR - http://www.scopus.com/inward/record.url?scp=77649207564&partnerID=8YFLogxK
U2 - 10.3109/15622970903555881
DO - 10.3109/15622970903555881
M3 - Review article
C2 - 20148751
AN - SCOPUS:77649207564
SN - 1562-2975
VL - 11
SP - 81
EP - 109
JO - World Journal of Biological Psychiatry
JF - World Journal of Biological Psychiatry
IS - 2
ER -